01:26 AM EDT, 09/08/2026 (MT Newswires) -- Swiss drugmaker Sandoz Group (SDZ.SW) plans to invest $300 million to develop a new biosimilar drug substance facility in Ljubljana, Slovenia. The facility would add 8,000 liters of capacity through four disposable fed-batch reactors, supporting both clinical and commercial manufacturing, according to a Tuesday release. The new facility is expected to boost the company's end-to-end biosimilar development, manufacturing, and supply network in Europe.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.